SYGNIS AG

EANS-News: SYGNIS announces three months results of fiscal year 2010/2011

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

3-month report

Heidelberg (euro adhoc) - Press release

@@start.t2@@Heidelberg,  August  12,  2010  -  SYGNIS  Pharma  AG  (Frankfurt:    LIO;    ISIN DE0005043509; Prime Standard) today reports  financial  results  for  the  first quarter of the fiscal year 2010/2011 ended June 30, 2010.

Financials

      • Cash including marketable securities amounted to EUR13.1 million as of
June 30, 2010 (EUR19.4 million Q1 2009/2010).  Long  term  financial
liabilities amounted to EUR8.0 million resulting from  a  loan  which  is  not
due  for repayment before 2015.

      • Total operating expenses for the quarter was EUR2.5 million, which  was
the same as the first three months of 2009/2010.@@end@@

• The net loss in the first quarter was EUR-2.3 million, which was the same as the previous year.

Milestones

@@start.t3@@• Patient recruitment for the phase II efficacy study of the Company´s lead
         compound AX200, for the treatment of acute ischemic stroke, has
         significantly increased following the implementation of the modification
         of the AXIS 2 study protocol.
      • At its first meeting on 2 August 2010, the Data  Safety  Monitoring  Board
         (DSMB) reviewed the data on the safety  and  tolerability  of  the  AXIS 2
         study medication and advised on the  continuation  of  the  study  without
         changes.@@end@@

Outlook

SYGNIS confirms its expectations of a net loss of around  EUR15   million  for the current 2010/2011 fiscal year and a liquidity outflow of some EUR14 million.

Due to the modification to the AXIS 2 study protocol  and  the   acceleration  of patient recruitment, the Company expects to present its initial findings of  the study by mid-2011.

In addition the Company  continues  to  evaluate  opportunities  to   extend  its product pipeline and is working towards concluding a research alliance  for  the KIBRA project.

@@start.t4@@|Key financial figures for the first quarter of fiscal year              |
|2010/2011 ended June 30, 2010 and corresponding figures (IFRS)        |
|Numbers in million euros                |Q1 2010/2011      |Q1 2009/2010      |
|Revenues                                         |0.1                    |0.0                    |
|Total expenses                                |2.5                    |2.5                    |
|EBIT                                                |-2.4                  |-2.4                  |
|Net results for the period            |-2.3                  |-2.3                  |
|Intangible assets                          |21.8                  |22.2                  |
|Liquidity at end of quarter          |13.1                  |19.4                  |
|Equity                                            |27.7                  |34.1                  |
|(equity ratio in %)                        |(69)                  |(72)                  |
|Long-term financial liabilities    |8.0                    |8.0                    |
|Operating Cash Flow                        |-2.3                  |-3.0                  |@@end@@

The report on the first quarter which ended on June 30,  2010  is   available  at the SYGNIS webpage at www.sygnis.de.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,   is  a  specialty  pharmaceutical company listed on the Prime Standard of the German stock exchange.  The  Company is focused on the research, development and marketing  of  innovative  therapies for the treatment of disorders of the  Central  Nervous  System.  These   include Stroke, Amyotrophic Lateral Sclerosis and neurological disorders resulting  from injuries to the brain or spinal cord. All these disorders are  characterized  by the fact that, as the disease progresses,  nerve  cells  are  damaged  and  die. Although there  is great  medical  demand,  there  are  currently  no  or  only inadequate treatment options available.

One of the central elements  in  this  value-creation  chain  is  the continued expansion of the existing product pipeline. This is achieved by the  development of new products as a result of SYGNIS´ own research  and  the  inorganic  growth through in-licensing agreements and  acquisitions.  By  means  of  specific  R&D programs at  SYGNIS,  new  pre-clinical  drug  candidates  are  identified   and evaluated as well as preclinical  projects  initiated,  which   are  offered  for inlicensing.

### Disclaimer Some statements included in this  press  release,   relating  neither  to  proven financial results nor other  historical data,  should  be  viewed  as  forward- looking, i.e. not definite. Such statements are  mainly  predictions  of  future results, trends, plans or goals. These statements should not  be  considered  to be total guarantees since given their very nature they are subject to known  and unknown risks and imponderability and can be affected  by other  factors  as  a consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG may deviate greatly from the   established  conclusions  or  implied  predictions contained in such statements. SYGNIS does not undertake to  publicly  update  or revise these statements in the light of new information  or  future  results or for any other reason. ###

@@start.t5@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
For further information please contact:

SYGNIS Pharma AG:
|Dr. Franz-Werner Haas                            |
|Vice President Operations                      |
|+49 (0) 6221 454 812                              |
|franz-werner.haas@sygnis.de                  |

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade
              München / free trade



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: